Kinase News and Research

RSS

Pathogens use previously undescribed mechanism to sabotage host immune system

New research identifies a previously unknown enzymatic mechanism that subverts the early host immune response and promotes pathogenicity by manipulating a common signaling pathway in host cells.

10 Dec 2007

Missing brain protein may be one of the culprits behind autism and other brain disorders

The protein helps synapses develop. Synapses--through which neurons communicate with one other-underlie our ability to learn and remember. Now Li-Huei Tsai, Picower Professor of Neuroscience at MIT, has uncovered an enzyme that is key to that protein's activity.

5 Dec 2007

Re-engineered Gleevec reduces heart risks

Using a new bottom-up approach for rational drug design, researchers at Rice University and the University of Texas M. D. Anderson Cancer Center have reengineered the powerful anticancer drug imatinib - best known by its brand name Gleevec - to more specifically target one type of cancer while potentially curbing a rare life-threatening cardiotoxic side effect.

4 Dec 2007

Modified form of imatinib becomes more specific

Imatinib (marketed as Gleevec in the US and Glivec in Europe and Australia) is used to treat various cancers, including chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs).

4 Dec 2007

Wyeth receives European approval for TORISEL

Wyeth Pharmaceuticals, a division of Wyeth, has announced that the European Commission has approved TORISEL (temsirolimus) for the first-line treatment of patients with advanced renal cell carcinoma (RCC) who have at least three of six prognostic risk factors. TORISEL is the only approved cancer therapy that specifically inhibits the mTOR (mammalian target of rapamycin) kinase, an important regulator of cell proliferation, cell growth and cell survival.

27 Nov 2007

Protein in mice known as RGS13 suppresses allergic reactions

A protein in mice known as RGS13 suppresses allergic reactions, including the severe, life-threatening allergic reaction known as anaphylaxis, according to scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

20 Nov 2007

U.S. approval of Nexavar (sorafenib) for inoperable liver cancer

The U.S. Food and Drug Administration has approved Nexavar (sorafenib) for use in patients with a form of liver cancer known as hepatocellular carcinoma, when the cancer is inoperable.

19 Nov 2007

CD200 stifles anti-tumor immunity

The prognosis for individuals with metastatic melanoma (MM) is not good. Therapeutic strategies to enhance the immune response have some clinical benefit; however, most patients eventually succumb to progressive disease, in part because their immune cells known as dendritic cells (DCs) fail to sustain an effective antitumor T cell immune response.

16 Nov 2007

Enzyme sphingosine kinase 2 show to be potential new target to fight cancer

Researchers at the Virginia Commonwealth University Massey Cancer Center have identified the enzyme sphingosine kinase 2 as a possible new therapeutic target to improve the efficacy of chemotherapy for colon and breast cancer.

2 Nov 2007

Discovery of master switch that regulates blood pressure

A team of Oregon Health & Science University researchers studying a rare form of hypertension has identified the mechanism by which they believe a protein complex in the kidney operates as a master switch that regulates blood pressure, a finding that has broad implications for the treatment of more common forms of hypertension.

2 Nov 2007

Emerging cancer therapies and novel targets

What are the cancer drugs of tomorrow and how will they be developed? At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, researchers will present some answers to these and other pressing questions regarding emerging cancer therapeutics.

25 Oct 2007

Blood markers can help choose best dose for antiangiogenic drugs

Scientists at Sunnybrook have new information that may help to improve the use of anti-cancer drugs designed to block the growth of new blood vessels in tumors, a process called angiogenesis that is critical to tumor growth.

25 Oct 2007

New target for Hepatocellular carcinoma therapy

Hepatocellular carcinoma (HCC) is a major health problem worldwide. Currently, the only chance for obtaining a cure in patients with HCC is by either a surgical resection or liver transplantation.

25 Oct 2007

Combination targets offer new hope in fight against cancer

While some targeted therapies - drugs developed to attack specific molecules in the critical chemical pathways occurring within cancer cells - work well by themselves, increasingly researchers are finding that they work better when teamed with other targeted and conventional therapies.

24 Oct 2007

Scientists uncover how hormones achieve their effects

The first quantitative study of protein complexes that transmit pheromone signals in living yeast cells sheds light on a crucial signalling process also found in humans.

22 Oct 2007

Bacteria use plant defence for genetic modification

Bacteria that cause tumours in plants modify plant genomes by skilfully exploiting the plants' first line of defence.

22 Oct 2007

New stem cells by reprogramming

Researchers are discovering new ways to help ‘de-program' specialised cells so that they can be re-programmed to form a range of different types of tissue, an international meeting of stem cell biologists was told.

18 Oct 2007

New knowledge about basic cancer biology

Merging technological innovations and new knowledge about basic cancer biology, cancer researchers now target specific molecules involved in critical chemical pathways of cancerous cells.

17 Oct 2007

RNA-binding protein key to understanding myotonic dystrophy type 1

Increased levels of a protein called CUGBP1 play an important role in the adult-onset form of muscular dystrophy called myotonic dystrophy type 1, said Baylor College of Medicine researchers in a report that appears in the journal Molecular Cell.

12 Oct 2007

Discovery of protein that plays a key role in the recycling of iron from blood

Scientists working in the only lab at MIT doing hematology research have uncovered a protein that plays a key role in the recycling of iron from blood. Their work, described in the October 11 Journal of Clinical Investigation, could lead to new therapies for certain inherited blood disorders such as beta-thalassemia, a condition that causes chronic anemia.

12 Oct 2007